Q2 2026 saw robust revenue and EPS growth, driven by strong clinical demand, expanding NovaSeq X placements, and innovation in multi-omics and AI-enabled offerings. Full-year guidance was raised for revenue and EPS, with clinical markets and new products expected to drive future growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.